Novocure Reports CE Mark Approval of Optune Lua for Metastatic NSCLC (mNSCLC)

Shots:Novocure has reported CE Mark approval of Optune Lua for mNSCLC adults progressed on Pt-based regimen based on P-III (LUNAR) trial assessing the treatment vs PD-1/PD-L1 inhibitors/docetaxel alone; launch in Germany is expected in coming wks.Trial showed improved OS (1EP), with an mOS of 13.2 vs 9.9mos. with treatment vs PD-1/PD-L1 inhibitors/docetaxel, 18.5…

ByRidhi RastogiApril 22, 2025

VIEWPOINTS

PharmaShots Interview: Novocure’s William F. Doyle Shares Insight on Company’s Accomplishments in the Treatment of Glioblastoma and Mesothelioma

In a recent interview with PharmaShots, William F. Doyle, Executive Chairman at Novocure shared information about the company's activities in the field of glioblastoma and mesothelioma. He also discussed the company's technology, Tumor Treating Fields (TTFields), and its potential for broad applicability across solid tumors.Shots:Novocure is a global oncology company working to extend survival…

BySenior EditorDecember 9, 2020

Novocure Reports CE Mark Approval of Optune Lua for Metastatic NSCLC (mNSCLC)

PharmaShots Interview: Novocure’s William F. Doyle Shares Insight on Company’s Accomplishments in the Treatment of Glioblastoma and Mesothelioma

Contact US

OUR INFORMATION

FOLLW US

Novocure Reports CE Mark Approval of Optune Lua for Metastatic NSCLC (mNSCLC)

PharmaShots Interview: Novocure’s William F. Doyle Shares Insight on Company’s Accomplishments in the Treatment of Glioblastoma and Mesothelioma

FOLLW US

Sign Up to Our Newsletter